OMP 313M32

Drug Profile

OMP 313M32

Alternative Names: Anti-TIGIT; Anti-TIGIT monoclonal antibody; OMP-313M32

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 09 Mar 2018 OncoMed Pharmaceuticals has issued and pending patents for OMP 313M32 in USA and other countries worldwide
  • 02 Nov 2017 OncoMed Pharmaceuticals plans a phase 1b trial for Solid tumours (Combination therapy) in the first half of 2018
  • 26 Apr 2017 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03119428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top